T. Rowe Price Associates
SGMT icon

T. Rowe Price Associates’s Sagimet Biosciences SGMT Stock Holding History

T. Rowe Price Associates’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
+48,883
New +$332K ﹤0.01% 2753
2025
Q2 		– Sell
-12,918
Closed -$43K – 3139
2025
Q1 		$43K Buy
+12,918
New +$54.2K ﹤0.01% 2947
2024
Q3 		– Sell
-10,069
Closed -$35K – 3024
2024
Q2 		$35K Sell
10,069
-6,636
-40% -$30.4K ﹤0.01% 2888
2024
Q1 		$91K Buy
+16,705
New +$120K ﹤0.01% 2798

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

T. Rowe Price Associates's SGMT Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 48,883 shares worth $378K. The stake represents ﹤0.01% of the portfolio and ranks #2753 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in SGMT as recently as Q1 2025.

T. Rowe Price Associates first reported a position in SGMT in Q1 2024 and has held it in 4 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • T. Rowe Price Associates held 48,883 shares of Sagimet Biosciences worth $378K as of Q2 2026.
  • Sagimet Biosciences was a new T. Rowe Price Associates position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2753 holding.
  • T. Rowe Price Associates first reported a position in Sagimet Biosciences in Q1 2024 and has held it in 4 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.